9.76
9.76 (0.47%)
As of Mar 06, 2024
Curis Inc [CRIS]
Source:
Company Overview
Curis Inc is a biotechnology company focused on the development of emavusertib (CA-4948), an orally available, small molecule inhibitor of Interleukin-1 receptor associated kinase, or IRAK4.
| Country | United States |
| Headquarters | lexington, massachusetts |
| Phone Number | 617-503-6500 |
| Industry | manufacturing |
| CEO | James Dentzer |
| Website | www.curis.com |